Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ETVAX

Financiado

Cerrado

ETVAX the first oral vaccine for protection against traveller s diarrhoea caus...

ETVAX the first oral vaccine for protection against traveller s diarrhoea caused by ETEC This project will perform a Phase II study of ETVAX – an oral vaccine against traveller’s diarrhoea (TD) caused by enterotoxigenic E. coli bacteria (ETEC). ETVAX has a strong potential to be the first vaccine with a full ETEC indi... ver más

31/05/2020

SBIO

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

SCANDINAVIAN BIOPHARMA HOLDING AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-05-31

SMEInst-05-2016-2017: Supporting innovative SMEs in the h...

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

SBIO

2.99M€ | Lider

Proyectos interesantes

SHIGETECVAX

Medical Technol...

Biotechnology

9M€ Cerrado

FILOVAX

Medical Technol...

Vaccinology

50M€ Cerrado

RTI2018-097625-B-I00

Medical Technol...

Biotechnology

290K€ Cerrado

PID2019-105761RB-I00

Medical Technol...

Public Health

106K€ Cerrado

PERISCOPE

Medical Technol...

Environmental S...

30M€ Cerrado

STOPENTERICS

Medical Technol...

Data Science

16M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 33 meses Fecha Inicio: 2017-08-09
Fecha Fin: 2020-05-31

Líder del proyecto

SCANDINAVIAN BIOPHARMA HOLDING AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto This project will perform a Phase II study of ETVAX – an oral vaccine against traveller’s diarrhoea (TD) caused by enterotoxigenic E. coli bacteria (ETEC). ETVAX has a strong potential to be the first vaccine with a full ETEC indication. TD caused by enterotoxigenic E. coli bacteria is the most common illness that affects travellers traveling in the developing regions. Currently, there is no approved method for preventing TD. Travellers are recommended to use off-label antibiotics such as Rifaximin or the cholera vaccine Dukoral to prevent TD. In business terms, there exists a strong business opportunity in developing and commercializing an effective and safe ETEC vaccine. Scandinavian Biopharma is the first SME positioned to capture this opportunity. The envisaged Phase II study will allow Scandinavian Biopharma take the key step towards the commercialization of ETVAX. The targeted users of are travellers visiting tropical and subtropical countries. Their number is forecasted to reach 190 million by 2020. Their key need is to prevent TD which can ruin a significant part of a vacation or a business trip. ETVAX will meet this needs by being safe, efficient and easy to use. The project delivers an ultimate EU added value by offering the first ETEC vaccine with proven immunogenicity, safety and efficacy. From the scientific perspective, this means that the project fills the gap in the vaccine research on the EU and global level as no other efficient methods for prevention of TD have been proposed on the market to date. The introduction of ETVAX will ultimately decrease number of TD cases among travellers, decrease number of patients with irritable bowel syndrome or other chronic diseases connected to TD, as well as decrease healthcare costs and productivity losses on the EU level. If successfully validated and accepted by regulatory bodies, ETVAX will take Scandinavian Biopharma to a new level of competitiveness and growth.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores